A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Exclusion Criteria

• •History of prior ≥ Grade 3 Cytokine Release Syndrome (CRS)
• •History of severe Infusion-Related Reactions (IRRs), allergic reactions, or hypersensitivity to any ingredients or components of the study treatments
• •Infection requiring systemic (oral or intravenous) therapy ≤ 14 days before the first dose of study drug(s), or participants with symptomatic COVID-19 infection
• •Active leptomeningeal disease or uncontrolled, untreated brain metastasis
• •Active autoimmune disease or history of autoimmune disease(s) that may relapse